Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
March 1, 2024 02:53 PM ESTUpdated March 5, 05:05 PM
R&D

Pfiz­er lays out am­bi­tious vi­sion for can­cer port­fo­lio in bid to rein­vig­o­rate its busi­ness

Lei Lei Wu

News Reporter

Pfiz­er hopes that its cur­rent pipeline could de­liv­er at least eight can­cer block­buster drugs by 2030 as part of its strat­e­gy to dou­ble down on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times